PubMed Health⌕ Search

PubMed · 1603095

Complement membrane attack complexes induce in human leukemic cells rapid expression of large proteins (L-CIP).

Abstract

The effect of sublytic doses of the complement membrane attack complexes (MAC) on protein synthesis in human leukemic cells was examined. As shown herein, rapid protein synthesis is evident in K562 erythroleukemic cells upon exposure to sublytic complement doses. Analysis of cell extracts by SDS-PAGE revealed high molecular weight proteins which appeared in the cells already after 15 min treatment with complement at 37 degrees C, reaching a maximal level after 40-50 min. These large complement-induced proteins (L-CIP) were clearly observed in gels stained by Coomassie blue and in autoradiograms following [35S]-Met or [3H]-Leu incorporation. Rabbit antibodies prepared against L-CIP were reactive in immunoassays with extracts of MAC-treated cells but not of non treated cells. They also bound to the surface of intact K562 cells (as determined by immunofluorescence), but only after treatment of the cells with complement. Both heterologous (rabbit and guinea pig) and homologous (human) sera induced L-CIP synthesis. The induction of L-CIP was indeed mediated by the complement MAC since L-CIP could not be detected in K562 cells exposed to heat-inactivated human serum or C6-deficient rabbit serum. Similarly, C7- or C8-deficient human sera could not induce L-CIP production unless they were reconstituted with purified human C7 or C8, respectively. The synthesis of L-CIP was largely inhibited by the protein synthesis inhibitors cycloheximide and puromycin and partially inhibited by the RNA synthesis inhibitor actinomycin D. L-CIP was similarly induced in two other human leukemic cell lines, U937 and HL-60, but not in K562/S, a subline of K562 which is highly sensitive to complement damage. These results are discussed with respect to the resistance of leukemic cells, and nucleated cells in general, to complement-mediated immune damage.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Y Reiter, Z Fishelson. 1992. Complement membrane attack complexes induce in human leukemic cells rapid expression of large proteins (L-CIP).. https://doi.org/10.1016/0161-5890(92)90187-3

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Designer TALEs enable discovery of cell death-inducer genes.

Transcription activator-like effectors (TALEs) in plant-pathogenic Xanthomonas bacteria activate expression of plant genes and support infection or cause a resistance response. PthA4AT is a TALE with a particularly short DNA-binding domain harboring only 7.5 repeats which triggers cell death in Nicotiana benthamiana; however, the genetic basis for this remains unknown. To identify possible target genes of PthA4AT that mediate cell death in N. benthamiana, we exploited the modularity of TALEs to stepwise enhance their specificity and reduce potential target sites. Substitutions of individual repeats suggested that PthA4AT-dependent cell death is sequence specific. Stepwise addition of repeats to the C-terminal or N-terminal end of the repeat region narrowed the sequence requirements in promoters of target genes. Transcriptome profiling and in silico target prediction allowed the isolation of two cell death inducer genes, which encode a patatin-like protein and a bifunctional monodehydroascorbate reductase/carbonic anhydrase protein. These two proteins are not linked to known TALE-dependent resistance genes. Our results show that the aberrant expression of different endogenous plant genes can cause a cell death reaction, which supports the hypothesis that TALE-dependent executor resistance genes can originate from various plant processes. Our strategy further demonstrates the use of TALEs to scan genomes for genes triggering cell death and other relevant phenotypes.

Cell Death↗

The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies.

For several decades, the clinical study of Parkinson's disease has driven an increasingly sophisticated understanding of the dopaminergic system and its complex role in modulating motor behavior. This article reviews salient areas of research in this field, commencing with the molecular biology of the development of the mesencephalic dopaminergic system. We then discuss events thought to be crucial in the cellular and molecular pathology of Parkinson's disease, proposed mechanisms of cell death, and relevant toxin models. These advancements are used as a template to review emerging therapeutic techniques, including neuroprotection strategies, surgical treatment of trophic factors, gene therapy, and neural transplantation.

Cell Death↗

In vitro cytotoxicity assessment.

The most frequent reason cited for withdrawal of an approved drug is toxicity, yet no simple solution exists to adequately predict such adverse effects. Compound prioritization and optimization during in vitro screening cascades need to be based on confidence, not only in efficacy and bioavailability, but also in safety. A wider number and diversity of potential molecular and cellular effects of compound interactions might affect safety than might affect efficacy or bioavailability. Accordingly, cytotoxicity assessment is less specific, more multiparametric, and extrapolatable with less certainty, unless there are specific safety signals indicated by the chemical structure or by precedents. Cytotoxicity assessments have been limited by their inability to measure multiple, mechanistic parameters that capture a wide spectrum of potential cytopathological changes. Assays with multiple parameters for key, multiple, and different features, such as in high content screening (HCS), are more predictive because they cover a wider spectrum of effects. Assays need to be applied to a large set of marketed drugs that produce toxicity by numerous and different mechanisms for assessment of correlation with human toxicity. This will enable determination of the concordance between in vitro and in vivo results. Multiparametric, live cell, prelethal cytotoxic HCS assays for assessing the potential of compounds for causing human toxicity address some of the limitations of traditional in vitro methods. Assays of this class were used to screen a library of drugs with varying degrees of toxicity and it was found that the sensitivity of the assays was 87%, whereas assay specificity was more than 90%, thereby minimizing false positives.

Cell Death↗